Continued treatment with gefitinib beyond progressive disease benefits patients with activating EGFR mutations (Q45238276)

From Wikidata
Jump to navigation Jump to search
scientific article published on 20 December 2012
edit
Language Label Description Also known as
English
Continued treatment with gefitinib beyond progressive disease benefits patients with activating EGFR mutations
scientific article published on 20 December 2012

    Statements

    Continued treatment with gefitinib beyond progressive disease benefits patients with activating EGFR mutations (English)

    Identifiers

     
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit
                    edit